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Background: In pts with heart failure (HF) and reduced ejection fraction (EF) guidelines recommend initiation of beta-blocker (βB) at a low dose 
with gradual uptitration as tolerated to doses used in clinical trials. However, the patterns and effects of βB intensification in the real-world setting 
remain poorly described.
Methods: We assembled a cohort of Kaiser Permanente of Colorado enrollees who had an index hospitalization for HF 2001-2008. Within this 
cohort, cases with subsequent rehospitalization were identified. Control pts without rehospitalization were matched by EF, age, sex, and year of 
cohort enrollment. The frequency of βB initiation or uptitration in the 60 days prior to first rehospitalization for cases was compared to controls 
during a 60-day interval at equal time from index hospitalization. Adjustment for differences in clinical characteristics was performed using 
conditional logistic regression. Secondary analysis determined adjusted rates of subsequent 60-day rehospitalization following initiation of high 
versus low dose βB (above or below the median dose).
Results: From the initial registry (n=2713), 46% had EF ≤40%, median age was 75 years, and 54% were women. During mean follow up of 531 
days, 69% of pts were rehospitalized and 45% died. Following index hospital discharge, 13% were never on βB, 24% were discharged without βB 
but subsequently initiated βB, 38% were discharged on βB but never uptitrated, and 25% had discharge βB uptitrated. From 1273 matched pairs, 
βB initiation or up-titration was more common in the 60 days before rehospitalization for cases in comparison to matched controls (6.4 v. 4.1%; 
adjusted OR 1.62, 95% CI 1.13-2.34). For those initiated on βB (n=639), rehospitalization rates over the next 60 days were similar for high versus 
low starting dose (10.2 v. 9.6%; adjusted OR 1.11, 95% CI 0.65-1.89).
Conclusions: Ambulatory βB intensification occurred in half of HF pts following hospital discharge and was independently associated 
with increased short-term rehospitalization. βB intensification appears to produce a transient period of higher risk, suggesting that gradual 
intensification coupled with closer monitoring may be warranted.
